Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
Boston ScientificBSX |
-$2.2B |
 |
MedtronicMDT |
-$80M |
 |
Edwards LifesciencesEW |
-$265M |
 |
Intuitive SurgicalISRG |
-$847M |
 |
ConmedCNMD |
-$2.6M |
Are Globus Medical Insiders Buying or Selling?
Globus Medical (GMED) has had 1 insider transaction in the past 90 days, all sells. The most recent was David Davidar, who sold 25,000 shares at $80.76 on June 5, 2026.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the GMED AI Score. For government officials trading this stock, see GMED congressional trading.
Who’s Trading Globus Medical Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| Daniel Scavilla | Sold $16M | 2 | Nov 21, 2024 |
| David Davidar | Sold $13M | 9 | Jun 5, 2026 |
| Kelly Huller | Sold $4.4M | 6 | Feb 25, 2026 |
| ANN RHOADS | Sold $3M | 5 | Nov 10, 2025 |
| STEPHEN ZARRILLI | Sold $2.1M | 1 | Nov 11, 2025 |
| Kyle Kline | Sold $2M | 2 | Jan 8, 2026 |
Recent Globus Medical Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| David Davidar | Jun 5, 2026 | Sell | 25,000 | $80.76 | $2M |
| Kelly Huller | Feb 25, 2026 | Sell | 20,000 | $94.5 | $1.9M |
| Kelly Huller | Feb 12, 2026 | Sell | 10,000 | $87.67 | $880,000 |
| Kyle Kline | Jan 8, 2026 | Sell | 3,594 | $101.1 | $360,000 |
| Leslie Norwalk | Jan 8, 2026 | Sell | 2,000 | $101.1 | $200,000 |
| Leslie Norwalk | Dec 12, 2025 | Sell | 4,000 | $88.85 | $360,000 |
| Kyle Kline | Dec 1, 2025 | Sell | 18,542 | $90 | $1.7M |
| Kelly Huller | Nov 25, 2025 | Sell | 7,500 | $90 | $680,000 |
| David Davidar | Nov 12, 2025 | Sell | 25,000 | $86 | $2.2M |
| STEPHEN ZARRILLI | Nov 11, 2025 | Sell | 25,000 | $84.29 | $2.1M |
| ANN RHOADS | Nov 10, 2025 | Sell | 2,000 | $85 | $170,000 |
| ANN RHOADS | Nov 7, 2025 | Sell | 8,000 | $81 | $650,000 |
| ANN RHOADS | Sep 15, 2025 | Sell | 10,000 | $58.46 | $580,000 |
| ANN RHOADS | Feb 28, 2025 | Sell | 7,500 | $78.68 | $590,000 |
| Keith Pfeil | Jan 10, 2025 | Sell | 12,501 | $88.17 | $1.1M |
| Keith Pfeil | Jan 10, 2025 | Sell | 1,666 | $89.17 | $150,000 |
| Kelly Huller | Dec 2, 2024 | Sell | 2,500 | $87 | $220,000 |
| David Davidar | Nov 22, 2024 | Sell | 6,766 | $85 | $580,000 |
| David Davidar | Nov 22, 2024 | Sell | 6,746 | $85 | $570,000 |
| Dan Lemaitre | Nov 22, 2024 | Sell | 1,097 | $85.02 | $93,000 |
| Daniel Scavilla | Nov 21, 2024 | Sell | 130,000 | $85 | $11M |
| David Davidar | Nov 21, 2024 | Sell | 13,254 | $85 | $1.1M |
| David Davidar | Nov 21, 2024 | Sell | 13,234 | $85 | $1.1M |
| Dan Lemaitre | Nov 21, 2024 | Sell | 13,278 | $85 | $1.1M |
| Daniel Scavilla | Nov 6, 2024 | Sell | 60,000 | $80.02 | $4.8M |
| Kelly Huller | Nov 6, 2024 | Sell | 2,500 | $82 | $210,000 |
| David Davidar | Oct 16, 2024 | Sell | 30,000 | $75.04 | $2.3M |
| David Davidar | Oct 16, 2024 | Sell | 20,000 | $75.03 | $1.5M |
| Kelly Huller | Oct 16, 2024 | Sell | 7,500 | $75.02 | $560,000 |
| ANN RHOADS | Sep 13, 2024 | Sell | 15,000 | $70.36 | $1.1M |
| David Davidar | Sep 13, 2024 | Sell | 25,000 | $70.46 | $1.8M |
Frequently Asked Questions: Globus Medical Insider Trading
In the past 90 days, Globus Medical insiders have made 0 buys and 1 sell. The net selling may indicate insiders are taking profits or reducing exposure.
The most recent sale was by David Davidar who sold 25,000 shares on June 5, 2026. View all transactions in the table on this page.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Scavilla Daniel T has sold the most GMED stock in the last 2 years, with a total value of $16M.
The total value of insider transactions for Globus Medical in the last 2 years is negative, amounting to -$44M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
